Seeking Alpha

Johnson & Johnson (JNJ +0.3%) subsidiary Janssen Pharmaceutical days the FDA has approved a...

Johnson & Johnson (JNJ +0.3%) subsidiary Janssen Pharmaceutical days the FDA has approved a broader indication for Zytiga. The drug, in combination with prednisone, may now be used earlier in the treatment continuum, before the use of chemotherapy. Zytiga also received a positive opinion for an expanded indication from the EMA and is under review by other health authorities worldwide.
Comments (1)
  • Old Trader
    , contributor
    Comments (5726) | Send Message
     
    It seems that slowly, but surely, the news flow re: JNJ is turning positive.
    10 Dec 2012, 04:39 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs